Comparison of the effects on glycaemic control and β‐cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel‐group trial (the CONFIDENCE study)

Progressive β‐cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β‐cell‐protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and impact on β‐cell function of three antihyperglycaemic agents that have a β‐cell‐protective effect, exenatide, insulin and pioglitazone, in newly diagnosed patients with type 2 diabetes.

[1]  B. Zinman,et al.  Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.

[2]  R. Wender,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[3]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[4]  C. Ahn,et al.  Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus , 2012, Journal of diabetes investigation.

[5]  Yan Gao,et al.  Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. , 2012, Chinese medical journal.

[6]  M. Hanefeld,et al.  Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) , 2012, Diabetes Care.

[7]  S. Gough,et al.  Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme , 2012, Diabetes, obesity & metabolism.

[8]  M. Taskinen,et al.  Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes , 2011, Diabetes Care.

[9]  Gretchen A. Stevens,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[10]  B. Hoogwerf,et al.  Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies , 2010, Diabetes Care.

[11]  S. Brichard,et al.  Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. , 2010, Diabetes & metabolism.

[12]  R. Bergenstal,et al.  Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.

[13]  J. Northrup,et al.  Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial , 2010, The Lancet.

[14]  G. Bray,et al.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study , 2010, Diabetologia.

[15]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[16]  R. DeFronzo,et al.  Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels , 2009, Diabetes Care.

[17]  B. Wolffenbuttel,et al.  Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  B. Wajchenberg.  beta-cell failure in diabetes and preservation by clinical treatment. , 2007, Endocrine reviews.

[19]  D. Bell.  Management of Type 2 Diabetes With Thiazolidinediones , 2004 .

[20]  S. Kahn,et al.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes , 2003, Diabetologia.

[21]  F. Ovalle,et al.  Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus , 2002, Diabetes, obesity & metabolism.

[22]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[23]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[24]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[25]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[26]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[27]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[28]  Qian Rong-l,et al.  A better comprehension of “Management of Hyperglycemia in Type 2 Diabetes:A Patient-Centered Approach—Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)” , 2013 .

[29]  J. Best,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .